DNA甲基化特征预测晚期非小细胞肺癌抗PD-1治疗反应:多中心回顾性分析
该多中心回顾性研究纳入142例IV期NSCLC患者,建立并验证DNA甲基化特征EPIMMUNE及FOXP1单甲基化标志物。EPIMMUNE阳性与更优无进展生存和总生存相关,且独立于PD-L1表达、CD8+细胞及突变负荷;FOXP1去甲基化同样与更好生存相关。
要点
- EPIMMUNE阳性特征与抗PD-1治疗后的无进展生存和总生存改善相关。
- EPIMMUNE阳性与PD-L1表达、CD8+细胞及突变负荷无关。
- FOXP1去甲基化与抗PD-1治疗患者的无进展生存和总生存改善相关。
核心结论
- NSCLC肿瘤的表观遗传特征可提示哪些患者最可能从纳武利尤单抗或帕博利珠单抗治疗中获益。
- FOXP1甲基化状态可与PD-L1染色及突变负荷等已验证预测生物标志物联合,以更好地筛选从PD-1阻断中获益的患者。
研究设计与样本
- 多中心回顾性研究,招募法国、西班牙和意大利15家医院的成人IV期NSCLC患者,均在病程中接受过PD-1阻断治疗。
- 研究结构包括一个发现队列和两个验证队列,分别评估表观遗传特征与临床获益的相关性及假设的 validity。
- 共获取142例患者样本:发现队列34例,EPIMMUNE验证队列47例,FOXP1衍生甲基化标志物验证队列61例。
主要发现
- 在发现队列中,EPIMMUNE特征与接受抗PD-1治疗的IV期NSCLC患者改善的无进展生存相关(HR 0·010,95% CI 3·29×10⁻⁴–0·0282;p=0·0067)。
- EPIMMUNE特征与改善的总生存相关(HR 0·080,95% CI 0·017–0·373;p=0·0012)。
- EPIMMUNE阳性特征与PD-L1表达、CD8+细胞存在或突变负荷无关。
- EPIMMUNE阴性肿瘤富集肿瘤相关巨噬细胞和中性粒细胞、癌相关成纤维细胞及衰老内皮细胞。
- 在EPIMMUNE验证队列中,EPIMMUNE阳性特征与改善的无进展生存相关(HR 0·330,95% CI 0·149–0·727;p=0·0064)。
关键数值与推荐
- EPIMMUNE特征基于微阵列DNA甲基化签名在发现集肿瘤样本中建立,患者接受纳武利尤单抗或帕博利珠单抗治疗。
- EPIMMUNE特征在独立患者集中验证,FOXP1衍生DNA甲基化标志物通过单甲基化检测在验证队列中验证。
- 主要研究结局为无进展生存和总生存,采用Kaplan-Meier法估计,log-rank检验比较组间差异,多变量Cox模型识别独立相关变量。
临床怎么用
- EPIMMUNE特征和FOXP1甲基化状态可能帮助识别最可能从纳武利尤单抗或帕博利珠单抗治疗中获益的IV期NSCLC患者。
- FOXP1甲基化状态可与PD-L1染色和突变负荷等已验证生物标志物联合使用,以优化PD-1阻断治疗的患者选择。
- 上述甲基化标志物的预测价值尚需在前瞻性研究中评估。
局限性
- 本研究为回顾性分析,样本来自发现队列和验证队列共142例患者。
- EPIMMUNE特征和FOXP1未甲基化的预测价值尚需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of patients do not respond to this treatment. We examined the use of DNA methylation profiles to determine the efficacy of anti-PD-1 treatment in patients recruited with current stage IV NSCLC. METHODS: In this multicentre study, we recruited adult patients from 15 hospitals in France, Spain, and Italy who had histologically proven stage IV NSCLC and had been exposed to PD-1 blockade during the course of the disease. The study structure comprised a discovery cohort to assess the correlation between epigenetic features and clinical benefit with PD-1 blockade and two validation cohorts to assess the validity of our assumptions. We first established an epigenomic profile based on a microarray DNA methylation signature (EPIMMUNE) in a discovery set of tumour samples from patients treated with nivolumab or pembrolizumab. The EPIMMUNE signature was validated in an independent set of patients. A derived DNA methylation marker was validated by a single-methylation assay in a validation cohort of patients. The main study outcomes were progression-free survival and overall survival. We used the Kaplan-Meier method to estimate progression-free and overall survival, and calculated the differences between the groups with the log-rank test. We constructed a multivariate Cox model to identify the variables independently associated with progression-free and overall survival. FINDINGS: Between June 23, 2014, and May 18, 2017, we obtained samples from 142 patients: 34 in the discovery cohort, 47 in the EPIMMUNE validation cohort, and 61 in the derived methylation marker cohort (the T-cell differentiation factor forkhead box P1 [FOXP1]). The EPIMMUNE signature in patients with stage IV NSCLC treated with anti-PD-1 agents was associated with improved progression-free survival (hazard ratio [HR] 0·010, 95% CI 3·29 × 10-4-0·0282; p=0·0067) and overall survival (0·080, 0·017-0·373; p=0·0012). The EPIMMUNE-positive signature was not associated with PD-L1 expression, the presence of CD8+ cells, or mutational load. EPIMMUNE-negative tumours were enriched in tumour-associated macrophages and neutrophils, cancer-associated fibroblasts, and senescent endothelial cells. The EPIMMUNE-positive signature was associated with improved progression-free survival in the EPIMMUNE validation cohort (0·330, 0·149-0·727; p=0·0064). The unmethylated status of FOXP1 was associated with improved progression-free survival (0·415, 0·209-0·802; p=0·0063) and overall survival (0·409, 0·220-0·780; p=0·0094) in the FOXP1 validation cohort. The EPIMMUNE signature and unmethylated FOXP1 were not associated with clinical benefit in lung tumours that did not receive immunotherapy. INTERPRETATION: Our study shows that the epigenetic milieu of NSCLC tumours indicates which patients are most likely to benefit from nivolumab or pembrolizumab treatments. The methylation status of FOXP1 could be associated with validated predictive biomarkers such as PD-L1 staining and mutational load to better select patients who will experience clinical benefit with PD-1 blockade, and its predictive value should be evaluated in prospective studies. FUNDING: "Obra Social" La Caixa, Cellex Foundation, and the Health and Science Departments of the Generalitat de Catalunya.
引用
- Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med. 2018. PMID: 30100403. doi:10.1016/S2213-2600(18)30284-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。